Loading...
•
Dec 31, 2025
Ocuphire Q4 2025 Earnings Report
Opus Genetics did not separately report standalone fourth-quarter results, so the quarter was reconstructed from the full-year 2025 report and the first three quarterly reports.
Key Takeaways
Using the full-year 2025 filing and the previously reported first three quarters, Opus Genetics generated an estimated $3865000 of Q4 2025 collaboration revenue and an estimated net loss of $16523000. The quarter reflected higher R&D spending as the company advanced its gene therapy pipeline, while year-end cash and cash equivalents were $45091000.
Standalone Q4 2025 revenue was reconstructed at $3865000 from full-year and first-nine-month reported figures.
Estimated Q4 2025 net loss was $16523000, implying a wider loss than the first half of the year but lower than Q3 2025.
Estimated Q4 2025 research and development expense increased to $10428000.
Cash and cash equivalents at December 31, 2025 were $45091000.
Revenue by Segment
Forward Guidance
Opus Genetics highlighted multiple 2026 catalysts across its inherited retinal disease pipeline and phentolamine program, while stating that post-quarter financing should extend cash runway into the first half of 2028.
Positive Outlook
- Additional data from the BEST1 program are expected in mid-year 2026.
- The FDA set an October 17, 2026 PDUFA date for Phentolamine Ophthalmic Solution 0.75% in presbyopia.
- Phase 1/2 pediatric LCA5 data are expected at ARVO in May 2026.
- The company expects dosing with OPGx-LCA5 in the second half of 2026.
- Management said aggregate cash resources after the private placement should fund operations into the first half of 2028.
Challenges Ahead
- Standalone Q4 results were not explicitly reported by the company and had to be reconstructed.
- The company remained loss-making in Q4 2025.
- Revenue was still dependent on collaboration reimbursements rather than product sales growth.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...